Pharmaceutical cannabinoid API manufacturer and CDMO

OHANA Bio Pharma operates an integrated GACP/CMC/GMP platform that moves qualified cannabinoid plant material from controlled cultivation through pharmaceutical manufacturing, with full traceability and quality oversight. Starting with qualified seed or tissue-culture starter material, chemovars are selected by target chemotype and documented by genetic origin, propagation lot, and batch identity to support downstream CMC requirements and regulatory continuity. Cultivation occurs in climate-controlled indoor rooms, where light, temperature, humidity, VPD, air exchange, CO₂, and substrate conditions are continuously monitored and adjusted to ensure batch consistency and preserve intended cannabinoid and terpene profiles. Under GACP-aligned SOPs, agronomy and quality personnel manage propagation, sanitation, fertigation, plant health, harvest timing, and in-process inspection, maintaining complete batch records and chain-of-custody controls. Following harvest, biomass enters GMP-controlled curing, drying, milling, and packaging workflows, where validated environmental controls and release testing for identity, potency, and contaminants establish qualified intermediates suitable for regulated manufacturing. These intermediates then undergo GMP extraction, winterization, distillation, and purification to produce high-purity cannabinoid concentrates and APIs, supported by CMC documentation, stability programs, and manufacturing systems aligned with pharmaceutical expectations for clinical, 503B, and commercial applications.